<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392183</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0358</org_study_id>
    <secondary_id>NCI-2011-01277</secondary_id>
    <nct_id>NCT01392183</nct_id>
  </id_info>
  <brief_title>Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)</brief_title>
  <official_title>A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare pazopanib to temsirolimus in the&#xD;
      treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be&#xD;
      studied.&#xD;
&#xD;
      Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for&#xD;
      tumor growth. This may prevent or slow the growth of cancer cells.&#xD;
&#xD;
      Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells to&#xD;
      die.&#xD;
&#xD;
      This is an investigational study. Pazopanib and temsirolimus are both FDA approved and&#xD;
      commercially available for the treatment of kidney cancer. It is investigational to compare&#xD;
      the 2 drugs.&#xD;
&#xD;
      Up to 90 patients will be enrolled in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups and Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the flip of a coin) to 1 of 2 study groups. You will have an equal chance of being&#xD;
      assigned to either group.&#xD;
&#xD;
        -  If you are assigned to Group 1, you will take pazopanib by mouth 1 time every day at&#xD;
           about the same time each day on an empty stomach (at least 1 hour before or 2 hours&#xD;
           after a meal).&#xD;
&#xD;
        -  If you are assigned to Group 2, you will receive temsirolimus by vein 1 time every week&#xD;
           over 30-60 minutes. About 30 minutes before you receive each dose of temsirolimus, you&#xD;
           will receive Benadryl (diphenhydramine) by vein over 1-2 minutes to help lower the risk&#xD;
           of side effects.&#xD;
&#xD;
      If you are assigned to Group 1, do not crush tablets and do not repeat missed doses if it is&#xD;
      less than 12 hours until your next scheduled dose. You will be given a pill diary to record&#xD;
      when you take each dose. You will return the diary to the study doctor at each study visit.&#xD;
&#xD;
      If you have any side effects, you should tell the study doctor right away. If the study&#xD;
      doctor thinks it is in your best interest, your dose may be lowered.&#xD;
&#xD;
      If the disease gets worse while you are on study, you will have the option to change to the&#xD;
      study group you were not originally assigned to and take the other study drug. The study drug&#xD;
      dosing and study visit schedule will be the same, and the study doctor will discuss any&#xD;
      important details with you at the time you change study groups.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      Every 4 weeks on this study is called a study cycle.&#xD;
&#xD;
      Every week during Cycle 1 (Group 1 only), your blood pressure will be checked (either at&#xD;
      home, at the clinic, or by your local doctor). If you are checking your own blood pressure at&#xD;
      home, you will need to write down your blood pressure in a blood pressure diary each time you&#xD;
      check it and bring the diary with you to each clinic visit.&#xD;
&#xD;
      Every 2 weeks for the first 2 cycles (Group 1 only) , blood (about 3 tablespoons) will be&#xD;
      drawn for routine tests.&#xD;
&#xD;
      Every week (Group 2 only), blood (about 1 tablespoon) will be drawn for routine tests.&#xD;
&#xD;
      Every cycle (Group 2 only) OR Every other cycle (Group 1 only):&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your weight and vital signs.&#xD;
&#xD;
        -  You will be asked about any drugs or treatments you may be receiving.&#xD;
&#xD;
        -  You will be asked about any side effects you may have had.&#xD;
&#xD;
        -  Blood (about 3 tablespoons) will be collected for routine tests.&#xD;
&#xD;
      On Day 1 of Cycle 2, Day 1 of Cycle 4, and every 4 cycles after that (Group 1 only), you will&#xD;
      have an ECG to check your heart function.&#xD;
&#xD;
      If you are in Group 2 only, on Day 1 of Cycles 2, 3, and every other cycle after that (Cycles&#xD;
      5, 7, 9, and so on), blood (about 3 tablespoons) will be drawn for routine tests. You will be&#xD;
      asked to fast (eat nothing and drink only water) for at least 8 hours before those blood&#xD;
      draws.&#xD;
&#xD;
      Every 2 cycles:&#xD;
&#xD;
        -  You will have the same imaging scans that you had at screening. After 1 year on&#xD;
           treatment, these imaging scans may only be done every 3 cycles (Cycles 5, 8, 11, and so&#xD;
           on).&#xD;
&#xD;
        -  You will fill out the quality-of-life questionnaires.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for tests to check your thyroid function (Group&#xD;
           1 only).&#xD;
&#xD;
        -  Urine will be collected for routine tests.&#xD;
&#xD;
      Every 4 cycles, you will have an ECG (Group 2 only).&#xD;
&#xD;
      Every 6 cycles, you will have an ECHO or MUGA scan to check your heart function.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drug for as long as the doctor thinks it is in your best&#xD;
      interest. You will no longer be able to take a study drug if the disease gets worse, if&#xD;
      intolerable side effects occur, or if you are unable to follow study directions.&#xD;
&#xD;
      End-of-Treatment Follow- up:&#xD;
&#xD;
      About 30 days after you stop treatment, during a clinic visit or by phone, you will be asked&#xD;
      about any drugs or treatments you may be receiving and any side effects you may have had.&#xD;
&#xD;
      Long-Term Follow-up:&#xD;
&#xD;
      After you stop taking the study drug, the study staff will check up on you to ask how you are&#xD;
      doing about every 3 months from then on. The study staff will collect the information they&#xD;
      need either from your medical records or by calling you. If you are contacted by phone, the&#xD;
      call should only last about 5 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2012</start_date>
  <completion_date type="Actual">September 8, 2019</completion_date>
  <primary_completion_date type="Actual">September 8, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Measured form start of treatment up to 3 years</time_frame>
    <description>PFS is measured from the initiation of treatment to the time of first disease progression or death due to any reason during the first drug administration in each arm. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% or more increase in the sum of the longest diameters of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions. The PFS median of first drug pazopanib (treatment group) was compared to the PFS median of first drug temsirolimus (control group) in an adjusted Hazard ratio. The hazard ratio compares events from a treatment group to a control group. If the hazard ratio is greater than 1the treatment group performed better. If the hazard ratio is less than 1 the control group performed better. If the hazard ratio is equal to 1, then the groups performed equally.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the start of treatment up to 6 years or death, whichever came first</time_frame>
    <description>Overall survival is calculated from day of therapy initiation of the first administrated drug to the date of death. Kaplan-Meier estimator used to estimate the OS for each group of participants. The Overall Survival median of first drug pazopanib (treatment group) was compared to the Overall Survival median of first drug temsirolimus (control group) in an adjusted Hazard ratio. The hazard ratio compares events from a treatment group to a control group. If the hazard ratio is greater than 1the treatment group performed better. If the hazard ratio is less than 1 the control group performed better. If the hazard ratio is equal to 1, then the groups performed equally.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>800 mg by mouth daily in 4 week study cycle.</description>
    <arm_group_label>Pazopanib</arm_group_label>
    <other_name>GW786034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.</description>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Assessment</intervention_name>
    <description>Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.</description>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>Questionnaires</other_name>
    <other_name>Surveys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benadryl</intervention_name>
    <description>25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.</description>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>Diphenhydramine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologic confirmation of metastatic or locally advanced RCC with a major clear cell&#xD;
             component.&#xD;
&#xD;
          2. Measurable disease by RECIST criteria.&#xD;
&#xD;
          3. Age &gt;/= 18 years&#xD;
&#xD;
          4. ECOG performance status 0-2 or Karnofsky Performance Status &gt;/= 60%&#xD;
&#xD;
          5. Meets criteria for poor-risk defined as 3 or more of the following: ECOG performance&#xD;
             status 2, anemia (hemoglobin lower than reference range), elevated serum LDH &gt; 1.5x&#xD;
             upper limit of normal (ULN), hypercalcemia (corrected serum calcium level &gt; upper&#xD;
             limit of normal), time from initial RCC diagnosis to registration on this trial &lt; 1&#xD;
             year, and &gt; 1 metastatic organ sites.&#xD;
&#xD;
          6. Adequate organ and marrow function within 14 days of registration as defined below: a)&#xD;
             Absolute neutrophil count &gt;/=1,500/µL b) Platelets &gt;/=100,000/µL c) Hgb &gt;/= 9.0 g/dL&#xD;
             (transfusion allowed) d) Renal: serum creatinine &lt;/= 1.5 x ULN or calculated CrCl &gt;/=&#xD;
             40 cc/min and random urine protein:creatinine ratio (UPC) &lt; 1 or 24-hr urine protein &lt;&#xD;
             1g e) Liver: total bilirubin &lt;/= 1.5 mg/dl; AST (SGOT) and ALT (SGPT) &lt;/= 2.5 x ULN&#xD;
             for subjects without evidence of liver metastases, &lt;/= 5 x ULN for subjects with&#xD;
             documented liver metastases f) INR &lt;/= 1.2 x ULN; PTT &lt;/= 1.5 x ULN. Therapeutic&#xD;
             anticoagulation with warfarin is allowed if target INR &lt;/= 3 on a stable dose of&#xD;
             warfarin or on a stable dose of LMW heparin for &gt; 2 weeks (14 days) at time of&#xD;
             randomization.&#xD;
&#xD;
          7. Female patients of childbearing potential (not postmenopausal for at least 12 months&#xD;
             and not surgically sterile) must have a negative serum or urine pregnancy test within&#xD;
             14 days of study registration. Pregnancy test must be repeated if performed &gt; 14 days&#xD;
             before starting study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior malignancy, except for non-melanoma skin cancer, in situ carcinoma of any site,&#xD;
             or other cancers for which the patient has been adequately treated and disease free&#xD;
             for 2 years&#xD;
&#xD;
          2. Prior targeted therapy (anti-VEGF agents or mTOR inhibitors) including adjuvant&#xD;
             therapy, and prior chemotherapy for mRCC. However, prior immunotherapy (cytokines or&#xD;
             vaccines) is allowed.&#xD;
&#xD;
          3. Any experimental drug while on this study; however, concomitant bone targeted therapy&#xD;
             (bisphosphonates or the anti-RANK ligand denosumab) is allowed.&#xD;
&#xD;
          4. Uncontrolled brain metastases and infections. Patients with brain metastases treated&#xD;
             with Gamma Knife (GK) or whole brain radiation within 24 hours of registration.&#xD;
&#xD;
          5. History of stroke within 6 months of registration&#xD;
&#xD;
          6. Clinically significant cardiovascular disease, defined as myocardial infarction (or&#xD;
             unstable angina) within 6 months of registration, New York Heart Association (NYHA)&#xD;
             Grade II or greater congestive heart failure, serious cardiac dysrhythmia refractory&#xD;
             to medical management. However, treated and controlled or stable/not clinically&#xD;
             significant cardiovascular disease is allowed per evaluation by cardiologist.&#xD;
&#xD;
          7. Uncontrolled hypertension (home blood pressure readings are permitted) or prior&#xD;
             history of hypertensive crisis or hypertensive encephalopathy; however, treatment of&#xD;
             hypertension with medications is permitted.&#xD;
&#xD;
          8. History of uncontrolled hemoptysis (&gt;/= 1/2 teaspoon of bright red blood per episode)&#xD;
             within 1 month prior to Day 1&#xD;
&#xD;
          9. Significant vascular disease including aortic aneurysm, aortic dissection.&#xD;
&#xD;
         10. Symptomatic peripheral vascular disease&#xD;
&#xD;
         11. Pregnancy&#xD;
&#xD;
         12. HIV-positive patients receiving combination anti-retroviral therapy&#xD;
&#xD;
         13. Coagulopathy or bleeding diathesis&#xD;
&#xD;
         14. Concomitant treatment with rifampin, St. John's wort, or the cytochrome p450&#xD;
             enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or Phenobarbital)&#xD;
&#xD;
         15. Major surgery within 28 days prior to registration&#xD;
&#xD;
         16. Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device within 7 days prior to starting drug&#xD;
&#xD;
         17. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study registration&#xD;
&#xD;
         18. Serious non-healing wound&#xD;
&#xD;
         19. Baseline QTcB &gt;/= 470 msec.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amado Zurita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <results_first_submitted>August 21, 2020</results_first_submitted>
  <results_first_submitted_qc>August 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney cancer</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Poor-Risk Clear-Cell Renal Cell Carcinoma</keyword>
  <keyword>RCC</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Complete response</keyword>
  <keyword>CR</keyword>
  <keyword>Partial Response</keyword>
  <keyword>PR</keyword>
  <keyword>Overall survival</keyword>
  <keyword>OS</keyword>
  <keyword>Time to progression</keyword>
  <keyword>TTP</keyword>
  <keyword>Pazopanib</keyword>
  <keyword>GW786034</keyword>
  <keyword>Temsirolimus</keyword>
  <keyword>CCI-779</keyword>
  <keyword>Torisel</keyword>
  <keyword>Benadryl</keyword>
  <keyword>Diphenhydramine</keyword>
  <keyword>TemPa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT01392183/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 2012 to September 2017</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Temsirolimus (Control Group)</title>
          <description>Temsirolimus 25 mg intravenously weekly. Upon progression patient crosses over over to pazopanib 800 mg orally daily. Treatments stop for progression, toxicity, withdrawal, or death.</description>
        </group>
        <group group_id="P2">
          <title>Pazopanib (Treatment Group)</title>
          <description>Pazopanib 800 mg orally daily. Upon progression patient crosses over to temsirolimus 25 mg intravenously weekly. Treatments stop for progression, toxicity, withdrawal, or death.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Drug Administration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible to Cross Over to 2nd Drug</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Drug Administration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Ended: Progression</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Ended: Adverse Events</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Ended: Participant Withdrew</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Ended: Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temsirolimus (Control Group)</title>
          <description>Temsirolimus 25 mg intravenously weekly. Upon progression patient crosses over to pazopanib 800 mg orally daily. Treatments stop for progression, toxicity, withdrawal, or death.</description>
        </group>
        <group group_id="B2">
          <title>Pazopanib (Treatment Group)</title>
          <description>Pazopanib 800 mg orally daily. Upon progression patient crosses over to temsirolimus 25 mg intravenously weekly. Treatments stop for progression, toxicity, withdrawal, or death.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="42" upper_limit="80"/>
                    <measurement group_id="B2" value="61" lower_limit="37" upper_limit="74"/>
                    <measurement group_id="B3" value="61" lower_limit="37" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status (KPS) Score</title>
          <description>The KPS score measures the participant's ability to perform ordinary tasks from 100 % - 0%. 100% no signs of disease, 90% minor signs or symptoms of disease, 80% normal activity with effort, 70% cannot do normal daily activities, 60% requires occasional assistance, 50% requires considerable assistance and frequent medical care, 40% disabled requires special care, 30% severely disabled; hospital admission is indicated, 20% very sick; hospital admission needed for active supportive treatment, 10% fatal processes progressing rapidly, and 0% death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Score</title>
          <description>ECOG measures how how the disease impacts a participant's daily living abilities such as self-care, daily living activity, and physical ability. The scores ranges from grade 0-5: 0 fully active; 1 restricted in physically strenuous activity but can walk; 2 can walk, capable of all self-care, but cannot do any work activities; 3 capable of only limited self-care and confined to bed or chair more than 50% of waking hours; 4 completely disabled, cannot carry on any self-care, totally confined to bed or chair; and 5 death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Poor -Risk With Disease Eligibility Score.</title>
          <description>Participants were considered poor risk with at least 3 factors. The more risk factors the poorer the risk. The factors were any combination of an ECOG grade 2, anemia, high lactate dehydrogenase levels, high calcium levels, less than 1 year from diagnosis to the date of registration on this trial, or more than one organ with metastatic disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>3 Factors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Factors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Factors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Score</title>
          <description>The IMDC score determines the overall survival in participants treated with cancer medications. The score is based on the 6 following factors: less than 1 year from time of diagnosis to trial registration, KPS score of 80% or less, anemia, high levels of calcium, high levels of neutrophils (a type of white blood cell), and a high level of platelets. The scores ranges from 0 - 6. A favorable risk score is 0. An intermediate risk score is 1 - 2. A poor risk score is 3 - 6.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Favorable risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor Risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS is measured from the initiation of treatment to the time of first disease progression or death due to any reason during the first drug administration in each arm. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% or more increase in the sum of the longest diameters of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions. The PFS median of first drug pazopanib (treatment group) was compared to the PFS median of first drug temsirolimus (control group) in an adjusted Hazard ratio. The hazard ratio compares events from a treatment group to a control group. If the hazard ratio is greater than 1the treatment group performed better. If the hazard ratio is less than 1 the control group performed better. If the hazard ratio is equal to 1, then the groups performed equally.</description>
        <time_frame>Measured form start of treatment up to 3 years</time_frame>
        <population>The ratio is comparing both arms to each other, therefore the data would be identical.</population>
        <group_list>
          <group group_id="O1">
            <title>Temsirolimus (Control Group)</title>
            <description>Temsirolimus 25 mg intravenously weekly. Upon progression patient crosses over to pazopanib 800 mg orally daily. Treatments stop for progression, toxicity, withdrawal, or death.</description>
          </group>
          <group group_id="O2">
            <title>Pazopanib (Treatment Group)</title>
            <description>Pazopanib 800 mg orally daily. Upon progression patient crosses over to temsirolimus 25 mg intravenously weekly. Treatments stop for progression, toxicity, withdrawal, or death</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS is measured from the initiation of treatment to the time of first disease progression or death due to any reason during the first drug administration in each arm. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% or more increase in the sum of the longest diameters of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions. The PFS median of first drug pazopanib (treatment group) was compared to the PFS median of first drug temsirolimus (control group) in an adjusted Hazard ratio. The hazard ratio compares events from a treatment group to a control group. If the hazard ratio is greater than 1the treatment group performed better. If the hazard ratio is less than 1 the control group performed better. If the hazard ratio is equal to 1, then the groups performed equally.</description>
          <population>The ratio is comparing both arms to each other, therefore the data would be identical.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.2" upper_limit="24.6"/>
                    <measurement group_id="O2" value="5.2" lower_limit="0.4" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
            <estimate_desc>Adjusted Hazard Ratio comparing Median PFS of pazopanib (treatment group) to Temsirolimus (control group) as first line of treatment. HR &gt;1 treatment group performed better, &lt; 1 the control group performed better =1 groups performed equally.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is calculated from day of therapy initiation of the first administrated drug to the date of death. Kaplan-Meier estimator used to estimate the OS for each group of participants. The Overall Survival median of first drug pazopanib (treatment group) was compared to the Overall Survival median of first drug temsirolimus (control group) in an adjusted Hazard ratio. The hazard ratio compares events from a treatment group to a control group. If the hazard ratio is greater than 1the treatment group performed better. If the hazard ratio is less than 1 the control group performed better. If the hazard ratio is equal to 1, then the groups performed equally.</description>
        <time_frame>From the start of treatment up to 6 years or death, whichever came first</time_frame>
        <population>The ratio is comparing both arms to each other, therefore the data would be identical.</population>
        <group_list>
          <group group_id="O1">
            <title>Temsirolimus (Control Group)</title>
            <description>Temsirolimus 25 mg intravenously weekly. Upon progression patient crosses over to pazopanib 800 mg orally daily. Treatments stop for progression, toxicity, withdrawal, or death</description>
          </group>
          <group group_id="O2">
            <title>Pazopanib (Treatment Group)</title>
            <description>Pazopanib 800 mg orally daily. Pazopanib 800 mg orally daily. Upon progression patient crosses over to temsirolimus 25 mg intravenously weekly. Treatments stop for progression, toxicity, withdrawal, or death</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is calculated from day of therapy initiation of the first administrated drug to the date of death. Kaplan-Meier estimator used to estimate the OS for each group of participants. The Overall Survival median of first drug pazopanib (treatment group) was compared to the Overall Survival median of first drug temsirolimus (control group) in an adjusted Hazard ratio. The hazard ratio compares events from a treatment group to a control group. If the hazard ratio is greater than 1the treatment group performed better. If the hazard ratio is less than 1 the control group performed better. If the hazard ratio is equal to 1, then the groups performed equally.</description>
          <population>The ratio is comparing both arms to each other, therefore the data would be identical.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="2.4" upper_limit="68.8"/>
                    <measurement group_id="O2" value="11.9" lower_limit="1.3" upper_limit="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
            <estimate_desc>Adjusted HR comparing Median OS of pazopanib (treatment group) to Temsirolimus (control group) as first line of treatment. HR &gt;1 treatment group performed better, &lt; 1 the control group performed better =1 groups performed equally.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to study completion or date of death from any cause, whichever came first, assessed up to 5 years.</time_frame>
      <desc>The total at Risk are participants who received the intervention as their first drug or second drug. All participants did not received both drugs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Temsirolimus (Control Group)</title>
          <description>Temsirolimus 25 mg intravenously weekly. Upon progression patient crosses over to pazopanib 800 mg orally daily. Treatments stop for progression, toxicity, withdrawal, or death.</description>
        </group>
        <group group_id="E2">
          <title>Pazopanib (Treatment Group)</title>
          <description>Pazopanib 800 mg orally daily. Upon progression patient crosses over to temsirolimus 25 mg intravenously weekly. Treatments stop for progression, toxicity, withdrawal, or death.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain-cardic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skin breakdown</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="112" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E2" events="18" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="20" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" events="37" subjects_affected="16" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="24" subjects_affected="10" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="22" subjects_affected="14" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="85" subjects_affected="33" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="48" subjects_affected="27" subjects_at_risk="50"/>
                <counts group_id="E2" events="29" subjects_affected="12" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" events="79" subjects_affected="32" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="44" subjects_affected="23" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="45" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="65" subjects_affected="25" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="47" subjects_affected="19" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Alk Phos Increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" events="35" subjects_affected="17" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" events="53" subjects_affected="19" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="14" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chholesterol high</sub_title>
                <counts group_id="E1" events="31" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="127" subjects_affected="35" subjects_at_risk="50"/>
                <counts group_id="E2" events="38" subjects_affected="22" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypertriglyeridemia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="32" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Wall Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Generalized Muscle Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neuropahty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Parasthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" events="34" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E2" events="26" subjects_affected="15" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="36" subjects_affected="19" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hoarse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodeysesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="49" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E2" events="65" subjects_affected="22" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="38" subjects_affected="20" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="53" subjects_affected="26" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amado J. .Zurita-Saavedra, MD/ Associate Professor, Genitourinary Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713- 563-6966</phone>
      <email>azurita@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

